15
October

08:00 AM BST

Bioinformatics

Name: Drug Discovery Biology & Bioinformatics Strategy Meeting Europe 2025
Start: 2025-10-15T08:00
End: 2025-10-15T18:00
Location: Crowne Plaza, London Docklands

&

Drug Discovery Biology

Strategy Meeting Europe 2025

Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space

Crowne Plaza London Docklands

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Biology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitator

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.

Alan Palmer

Chief Executive Officer Elixa MediScience

Amir Lotfi

Senior Director, Nonclinical Beckley Psytech Limited

Andreas Arnell

Associate Director Bioinformatics AstraZeneca

Charles Bradshaw

Head of Bioinformatics Core The Gurdon Institute, Cambridge University

Chandan Seth Nanda

Entrepreneur in Residence Antler

Spearheading innovation at Pear Bio as Vice President of Target & Drug Discovery, her journey weaves a narrative of precision in oncology drug discovery. With a focus on early-phase drug discovery, HIT and LEAD identification, and biomarker integration, her expertise lays the groundwork for transformative cancer therapies. The strategic roadmap she helped develop for small biopharma positions Pear Bio at the forefront of the competitive oncology landscape. 
Her tenure with Pear Bio has been marked by the successful inception of drug discovery programs and securing substantial Series A funding, highlighting their company’s ascent in precision medicine. 
Collaboratively working with KOLs and CROs, she contributed to the success of Pear Bio as a companion diagnostics and targeted drug discovery company. In conjunction with our team, she is committed to delivering precision cancer therapeutics, fostering novel assets, and amplifying opportunities for the company.

Cristina Sisu

Associate Professor, Genomic Data Analytics Brunel University London

Jose Meseguer Ripolles

Group Leader, Translational Data Science Resolution Therapeutics

Juan Carlos Mobarec

Head Computational Structural Biology AstraZeneca

Matthew Fyfe

Chief Scientific Officer Outrun Tx

Nimesh Joseph Ph.D

Senior Field Application Scientist Revvity Signals

Stephen Harrison

Former CSO Nucleome Therapeutics

Steven Zimmer

CEO Dark Matter Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Alan	Palmer	Chief Executive Officer	Elixa MediScience	https://proventainternational.com/wp-content/uploads/2025/09/Alan-parmer.png
Amir	Lotfi	Senior Director, Nonclinical	Beckley Psytech Limited	https://proventainternational.com/wp-content/uploads/2025/09/Amir-Lotfi.jpg
Andreas	Arnell	Associate Director Bioinformatics	AstraZeneca	https://proventainternational.com/wp-content/uploads/2025/09/Andreas-Arnell.jpg	Andreas Arnell is an Associate Director, Bioinformatics at AstraZeneca in Cambridge, leading a cross‑functional team that accelerates biologics discovery and transforms wet‑lab workflows into robust data products. With over 15 years in biopharmaceutical discovery and development, he began in protein engineering and developability before pivoting to laboratory informatics and FAIR data management. He has product‑owned enterprise platforms, built scalable pipelines, and driven change management across R&D. Andreas is focused on the future of the Design‑Make‑Test‑Analyze (DMTA) cycle—what it will look like in five years, the solutions that will enable it, and how organizations can successfully manage the process transformation.
Charles	Bradshaw	Head of Bioinformatics Core	The Gurdon Institute, Cambridge University	https://proventainternational.com/wp-content/uploads/2020/03/Charles-Bradshaw.jpg	Topic: What can pharmaceutical R&D executives do to successfully lead human genetics-enabled R&D organizations? (2:30pm – 3:30pm)
Chandan	Seth Nanda	Entrepreneur in Residence	Antler	https://proventainternational.com/wp-content/uploads/2024/07/Chandan-Seth-Nanda-1.jpg	Spearheading innovation at Pear Bio as Vice President of Target & Drug Discovery, her journey weaves a narrative of precision in oncology drug discovery. With a focus on early-phase drug discovery, HIT and LEAD identification, and biomarker integration, her expertise lays the groundwork for transformative cancer therapies. The strategic roadmap she helped develop for small biopharma positions Pear Bio at the forefront of the competitive oncology landscape. Her tenure with Pear Bio has been marked by the successful inception of drug discovery programs and securing substantial Series A funding, highlighting their company’s ascent in precision medicine. Collaboratively working with KOLs and CROs, she contributed to the success of Pear Bio as a companion diagnostics and targeted drug discovery company. In conjunction with our team, she is committed to delivering precision cancer therapeutics, fostering novel assets, and amplifying opportunities for the company.
Cristina	Sisu	Associate Professor, Genomic Data Analytics	Brunel University London	https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg
Jose	Meseguer Ripolles	Group Leader, Translational Data Science	Resolution Therapeutics	https://proventainternational.com/wp-content/uploads/2025/05/Jose-Meseguer-Ripolles.jpg
Juan	Carlos Mobarec	Head Computational Structural Biology	AstraZeneca	https://proventainternational.com/wp-content/uploads/2025/09/Juan-Carlos-Mobarec.jpg
Matthew	Fyfe	Chief Scientific Officer	Outrun Tx	https://proventainternational.com/wp-content/uploads/2020/04/Matthew-Fyfe-1.jpg	Matthew Fyfe is Chief Scientific Officer at Outrun Therapeutics. He has over 25 years’ experience in drug discovery and development, having formerly held Senior Leadership positions at Storm Therapeutics, Sitryx, TopiVert, Oryzon and Prosidion. Matthew has successfully led diverse research programs and multidisciplinary teams in various therapeutic areas, delivering clinical candidates that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 100 published patent families.
Nimesh	Joseph Ph.D	Senior Field Application Scientist	Revvity Signals	https://proventainternational.com/wp-content/uploads/2025/09/Nimesh_Joseph.jpg	Nimesh Joseph is a Senior Field Application Scientist at Revvity Signals, helping Pharma/Biotech in their data digitalization journeys. He has more than 20 years of experience working in academic research labs and drug discovery biotech. He holds a master’s degree in Biotechnology and a Ph.D. in Biochemistry. His scientific training and research background includes biochemistry, molecular biology, Cell Biology, Genome Engineering, and pre-clinical drug discovery.
Stephen	Harrison	Former CSO	Nucleome Therapeutics	https://proventainternational.com/wp-content/uploads/2024/09/Stephen-Harrison.jpg
Steven	Zimmer	CEO	Dark Matter Therapeutics	https://proventainternational.com/wp-content/uploads/2020/03/Steven-Zimmer-1.jpg	Steven Zimmer is a biotechnology executive and strategic advisor working at the intersection of AI-driven drug discovery and longevity medicine. As CEO of Dark Matter Therapeutics (Watertown, MA), he leads an AI platform advancing programs in Opioid use disorder, neurodegenerative diseases and Kidney Fibrosis, including an NIH-funded collaboration with Hunter College/CUNY. He is also Co-founder, Director, and Strategic Advisor of Cortesi Longevity, a London-based private longevity advisory serving ultra-high-net-worth clients. His expertise spans AGE-RAGE biology, glycan and epigenetic aging biomarkers, and translational neuroscience. Based in Oxford, UK, Steven works closely with founders, scientists, and investors to build early-stage life sciences ventures. He is a trained Biochemist/Molecular Biologist and spent 20 years on Wall Street and the City of London as an analyst, investment banker and portfolio manager.

Alan Palmer, Amir Lotfi, Andreas Arnell, Charles Bradshaw, Chandan Seth Nanda, Cristina Sisu, Jose Meseguer Ripolles, Juan Carlos Mobarec, Matthew Fyfe, Nimesh Joseph Ph.D, Stephen Harrison, Steven Zimmer

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

08:30 - 09:00

AI driven approaches to Target, Drug & Biomarker Discovery

PRESENTER: Chandan Seth Nanda, Vice President of Target & Drug Discovery, Pear Bio

09:00 - 10:00

Roundtable Tracks

Target Identification & Hit Validation
Capturing the value of human disease genetics in target validation

-Stephen Harrison
Former CSO
Nucleome Therapeutics

DMPK / ADME & Toxicology
Bridging Preclinical Models and Human Safety: Innovations in DMPK and Toxicology

Data Management, Big Data & Digital Transformation
Can AI-Powered Drug Discovery transform How We Discover, Test, and Deliver Medicines?

-Steven Zimmer
CEO
Dark Matter Therapeutics

In Silico Biology / AI & ML
Accelerating Biologics R&D: Reinventing the DMTA Cycle with AI/ML

-Andreas Arnell
Associate Director Bioinformatics
AstraZeneca

11:10 - 12:10

Roundtable Tracks

Target Identification & Hit Validation
Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification

-Andreas Arnell
Associate Director Bioinformatics
AstraZeneca

Sponsor

DMPK / ADME & Toxicology
Bridging the translational gap with new approaches: Effectiveness of new methods in predicting human response compared to traditional animal models.

-Amir Lotfi
Senior Director, Nonclinical
Beckley Psytech Limited

Sponsor

Data Management, Big Data & Digital Transformation
Beyond the ELN: Turning Data Chaos into Connected Discovery

-Nimesh Joseph Ph.D
Senior Field Application Scientist
Revvity Signals

Revvity Signals

In Silico Biology / AI & ML
From Clusters to Cloud: Architecting High- Performance Storage for AI, Life Sciences, and the Next Wave of HPC Workloads

Sponsor

12:15 - 13:15

Roundtable Tracks

Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification

-May Rezai
Chief Operations Officer
MirZyme Therapeutics

Advancing Drug Discovery with Predictive Modeling, Metabolic Profiling, and ADME Optimization: Integrating DMPK Strategies to Enhance Pharmacokinetics and Bioavailability

-Matthew Fyfe
Chief Scientific Officer
Outrun Tx

The Convergence of Big Data and Biology: Digital Transformation in Sequencing, Data Integration, and High-Performance Computing

-Charles Bradshaw
Head of Bioinformatics Core
The Gurdon Institute, Cambridge University

Shaping Computational Strategy: Teams, AI Investments, and Partnerships in Drug Discovery

-Juan Carlos Mobarec
Head Computational Structural Biology
AstraZeneca

14:40 - 15:40

Roundtable Tracks

Target Identification & Hit Validation
Navigating the Integration of Artificial Intelligence in Drug Target Discovery

-Cristina Sisu
Associate Professor, Genomic Data Analytics
Brunel University London

DMPK / ADME & Toxicology
Strategies to Optimize ADME Properties in Drug Discovery to Enhance Drug Bioavailability

-Alan Palmer
Chief Executive Officer
Elixa MediScience

Data Management, Big Data & Digital Transformation
From Data Silos to Harmonized Discovery: Enabling Digital Change in Drug Development

-Jose Meseguer Ripolles
Group Leader, Translational Data Science
Resolution Therapeutics

In Silico Biology / AI & ML
Bridging the Data Divide in Bioinformatics: Innovative Approaches to Data Management and Analysis

-Chandan Seth Nanda
Entrepreneur in Residence
Antler

16:00 - 16:30

Overcoming Investment Barriers in Biotech: R&D Costs, IP Issues, and Market Uncertainty

PRESENTER: Stephen Harrison, Former CSO, Nucleome Therapeutics

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Europe

Medicinal Chemistry Strategy Meeting Europe 2024

&

Strategy Meeting Europe 2025

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Crowne Plaza London Docklands

Fresh Biology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitator

Alan Palmer

Amir Lotfi

Andreas Arnell

Charles Bradshaw

Chandan Seth Nanda

Cristina Sisu

Jose Meseguer Ripolles

Juan Carlos Mobarec

Matthew Fyfe

Nimesh Joseph Ph.D

Stephen Harrison

Steven Zimmer

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

AI driven approaches to Target, Drug & Biomarker Discovery

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking/1-1 Meetings

Roundtable ( Solution )

Roundtable Tracks

Sponsor

Sponsor

Revvity Signals

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Networking Lunch

Networking / 1-1 Meetings

Roundtable ( Pharma / Biotech)

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Overcoming Investment Barriers in Biotech: R&D Costs, IP Issues, and Market Uncertainty

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our 2025 Sponsors

Co-Host Sponsor

Partnering Sponsor

Key Opinion Leader

Our Media Partner

Become an official strategy meeting partner

Explore Highlight From The Past Events

Testimonials

Hotel & Venue

Crowne Plaza London Docklands

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

Crowne Plaza London Docklands